share_log

ProQR Therapeutics Analyst Ratings

Benzinga ·  Aug 7, 2023 18:14
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/07/2023 231.13% HC Wainwright & Co. → $5 Reiterates Buy → Buy
08/04/2023 32.45% Chardan Capital → $2 Reiterates Neutral → Neutral
05/17/2023 198.01% Cantor Fitzgerald $5 → $4.5 Maintains Overweight
05/17/2023 297.35% JMP Securities → $6 Reiterates Market Outperform → Market Outperform
05/17/2023 231.13% HC Wainwright & Co. → $5 Reiterates Buy → Buy
03/30/2023 297.35% JMP Securities → $6 Reiterates → Market Outperform
03/30/2023 231.13% HC Wainwright & Co. $1.5 → $5 Maintains Buy
12/23/2022 231.13% Raymond James $2 → $5 Maintains Outperform
12/22/2022 231.13% Cantor Fitzgerald $0.8 → $5 Upgrades Neutral → Overweight
08/15/2022 -0.66% HC Wainwright & Co. $2 → $1.5 Maintains Buy
08/12/2022 Chardan Capital Downgrades Buy → Neutral
08/12/2022 32.45% Raymond James → $2 Upgrades Market Perform → Outperform
05/09/2022 32.45% HC Wainwright & Co. $4 → $2 Maintains Buy
05/06/2022 32.45% Chardan Capital $2.5 → $2 Maintains Buy
04/14/2022 65.56% Chardan Capital $8 → $2.5 Maintains Buy
04/14/2022 231.13% JMP Securities $8 → $5 Maintains Market Outperform
02/14/2022 429.8% Chardan Capital $18 → $8 Maintains Buy
02/14/2022 429.8% JMP Securities $29 → $8 Maintains Market Outperform
02/14/2022 164.9% HC Wainwright & Co. $20 → $4 Maintains Buy
02/14/2022 Raymond James Downgrades Strong Buy → Market Perform
02/01/2022 1158.28% Raymond James → $19 Initiates Coverage On → Strong Buy
08/09/2021 1092.05% Chardan Capital $20 → $18 Maintains Buy
05/03/2021 1224.5% Stifel → $20 Initiates Coverage On → Buy
08/11/2020 1224.5% Chardan Capital $25 → $20 Maintains Buy
11/19/2019 2085.43% Citigroup $40 → $33 Maintains Buy
11/14/2018 2549.01% Cantor Fitzgerald → $40 Initiates Coverage On → Overweight
09/19/2018 2217.88% Evercore ISI Group → $35 Initiates Coverage On → Outperform

What is the target price for ProQR Therapeutics (PRQR)?

The latest price target for ProQR Therapeutics (NASDAQ: PRQR) was reported by HC Wainwright & Co. on August 7, 2023. The analyst firm set a price target for $5.00 expecting PRQR to rise to within 12 months (a possible 231.13% upside). 12 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for ProQR Therapeutics (PRQR)?

The latest analyst rating for ProQR Therapeutics (NASDAQ: PRQR) was provided by HC Wainwright & Co., and ProQR Therapeutics reiterated their buy rating.

When is the next analyst rating going to be posted or updated for ProQR Therapeutics (PRQR)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ProQR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ProQR Therapeutics was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.

Is the Analyst Rating ProQR Therapeutics (PRQR) correct?

While ratings are subjective and will change, the latest ProQR Therapeutics (PRQR) rating was a reiterated with a price target of $0.00 to $5.00. The current price ProQR Therapeutics (PRQR) is trading at is $1.51, which is within the analyst's predicted range.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment